SCHEMBL23064641

SCHEMBL23064641

Clc1ccc(C2CCCN2Cc2ccccc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.54
DRD4 P21917 1/20 0.54
DRD3 P35462 1/20 0.54
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
SIGMAR1 Q99720 2/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
RORC P51449 1/20 0.47
TMEM97 Q5BJF2 1/20 0.45
OPRM1 P35372 1/20 0.45
OPRK1 P41145 1/20 0.45
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45
APH1B Q8WW43 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23064631 0.94 MEN1 (0.55) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL22201130 0.90 CHRNB2 (0.53) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL2172790 0.90 CHRNB2 (0.53) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL2047049 0.86 HTR1A (0.49) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL24365232 0.85 KDM4E (0.56) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL11488897 0.85 KDM4E (0.56) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL9070276 0.83 DRD2 (0.53) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL2041903 0.82 L3MBTL1 (0.48) DRD2DRD4DRD3ALDH1A1KDM4E
SCHEMBL28312282 0.82 OPRK1 (0.61) ALDH1A1KDM4ESIGMAR1MEN1KMT2A
SCHEMBL5496178 0.81 OPRK1 (0.53) L3MBTL1OPRM1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4545515-A1 BCL-2 INHIBITORS BeiGene Switzerland GmbH (CH) 2025-04-30 EP disclosed
US-20240376104-A1 Bcl-2 Inhibitors BEIGENE LTD. (KY) 2024-11-14 US disclosed
US-12077536-B2 BCL-2 inhibitors BEIGENE, LTD. (KY) 2024-09-03 US disclosed
CN-117683029-A Bcl-2 inhibitors 百济神州有限公司 2024-03-12 CN disclosed
CN-117430601-A Bcl-2 inhibitors 百济神州有限公司 2024-01-23 CN disclosed
CN-112437772-B Bcl-2 inhibitors 百济神州有限公司 2023-11-21 CN disclosed
US-20220402915-A1 BCL-2 INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-12-22 US disclosed
US-20220402915-A1 BCL-2 INHIBITORS BEONE MEDICINES I GMBH (CH) 2022-12-22 US disclosed
US-11420968-B2 Bcl-2 inhibitors BEIGENE, LTD. (KY) 2022-08-23 US disclosed
EP-3788042-A1 BCL-2 INHIBITORS BeiGene, Ltd. (KY) 2021-03-10 EP disclosed
CN-112437772-A Bcl-2 inhibitors 百济神州有限公司 2021-03-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402915-A1 BCL-2 INHIBITORS BCL2, BCL2L1, BCL2L2 DRD2 4268/4885DRD4 4714/4885DRD3 4706/4885
US-11420968-B2 Bcl-2 inhibitors BCL2, BCL2L1, BCL2L2 DRD2 4268/4885DRD4 4714/4885DRD3 4706/4885
US-12077536-B2 BCL-2 inhibitors BCL2, BCL2L1, BCL2L2 DRD2 4268/4885DRD4 4714/4885DRD3 4706/4885
US-20240376104-A1 Bcl-2 Inhibitors BCL2, BCL2L1, BCL2L2 DRD2 4268/4885DRD4 4714/4885DRD3 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.